Teva Shifts Strategy In Japan
Teva Takeda Divests To Nichi-Iko; Focuses On Complex Generics And Specialty
Teva has announced a major strategic shift in Japan, with its Teva Takeda Pharma joint venture striking a deal to divest the majority of its traditional generics business to Nichi-Iko so that it can focus instead on complex generics and specialty products.
You may also be interested in...
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.